Maike J.M. Uijen

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Bastiaan M. Privé, Steffie M. B. Peters, Inge M. van Oort et al. · Clinical Cancer Research · 2021 · 89 citations · Full text

Out-of-hours primary care in 26 European countries: an overview of organizational models

Luca Steeman, Maike J.M. Uijen, Erik Plat et al. · Family Practice · 2020 · 67 citations · Full text

Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry

Maike J.M. Uijen, Bastiaan M. Privé, Carla M.L. van Herpen et al. · Nuclear Medicine Communications · 2023 · 28 citations · Full text

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma

Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen–van Grunsven et al. · Oral Oncology · 2022 · 24 citations · Full text

Degree of nephrotoxicity after intermediate‐ or high‐dose cisplatin‐based chemoradiotherapy in patients with locally advanced head and neck cancer

C.M.L. Driessen, Maike J.M. Uijen, Winette T.A. van der Graaf et al. · Head & Neck · 2015 · 22 citations · Full text